ストックスクリーナーアプリを入手
19.12
2.99%
-0.59
アフターアワーズ：
19.12
Acadia Pharmaceuticals Inc (ACAD) 最新ニュース
Press Release Distribution & Media Outreach Platform for PR Agencies - ACCESS Newswire
UBS cuts target for ACADIA Pharmaceuticals stock to USD 23.00 - ad-hoc-news.de
ACADIA Pharmaceuticals Inc. (ACAD) Stock Forecasts - Yahoo Finance
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc.ACAD - PR Newswire
ACADIA Pharmaceuticals Inc. (ACAD) Stock Forecasts - Yahoo! Finance Canada
ACADIA Pharmaceuticals Inc. (ACAD) Stock forecasts - Yahoo Finance UK
Law firm probes ACADIA investors' claims after trial misses key endpoint, stock drops sharply. - Pluang
Acadia Pharmaceuticals stock hits 52-week low at 19.01 USD - Investing.com
Can Nuplazid and Daybue Strengthen Acadia's Growth Prospects? - Zacks Investment Research
UBS Downgrades ACADIA Pharmaceuticals to Neutral From Buy, $23 Price Target - Yahoo Finance
4 CNS Drug Stocks Worth Watching This World Mental Health Day - Zacks Investment Research
RBC Trims Price Target on ACADIA Pharmaceuticals to $36 From $37, Keeps Outperform Rating - Yahoo Finance
ACADIA Pharmaceuticals Inc. (ACAD) Stock Forecasts - Yahoo Finance
RBC keeps Outperform on ACADIA Pharmaceuticals stock at USD 37 - AD HOC NEWS
RBC reiterates Outperform on ACADIA Pharmaceuticals stock - AD HOC NEWS
Acadia Pharmaceuticals (ACAD) Secures Patent And Phase 2 Progress, Is It 38% Below Fair Value? - Yahoo Finance
Acadia Pharmaceuticals (ACAD) Resolves Nuplazid Patent Dispute, Boosting Market Outlook - GuruFocus
RBC Capital reiterates Acadia Pharmaceuticals stock rating on patent developments - Investing.com
Acadia Pharmaceuticals (ACAD) and Zydus Move to Dismiss Patent L - GuruFocus
ACADIA Pharmaceuticals Inc. (0A4W.IL) Stock Price, News, Quote & History - Yahoo! Finance Canada
ACADIA Pharmaceuticals Inc. (ACAD) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
ACADIA Pharmaceuticals Inc. (ACAD) Stock forecasts - Yahoo Finance Australia
Acadia Pharmaceuticals stock hits 52-week low at $19.66 - Investing.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc.ACAD - PR Newswire
ACADIA Pharmaceuticals Inc. (ACAD) Stock Forecasts - Yahoo Finance
Acadia's Daybue Patent Allowance Extends U.S. Protection to March 2041 - Zacks Investment Research
Acadia's Daybue Patent Allowance Extends U.S. Protection to March 2041 - Yahoo Finance
Acadia debuts 63,000 sq. ft. Princeton office, biopharma hub designed by Ware Malcomb - Real Estate NJ
Acadia Pharmaceuticals Announces Allowance of U.S. Patent Covering Weight-Banded Dosing of Trofinetide, extending U.S. patent protections to March 2041 - biospace.com
Acadia Pharmaceuticals (ACAD) Secures USPTO Notice of Allowance for Rett Syndrome Patent - GuruFocus
Acadia Pharmaceuticals Gets US Patent Office Allowance for Trofinetide Dosing Patent - Yahoo Finance
Acadia Pharmaceuticals Announces Allowance of U.S. Patent Covering Weight-Banded Dosing of Trofinetide, extending U.S. patent protections to March 2041 - Yahoo Finance
Acadia Pharmaceuticals (ACAD) Stock Trades At A Discount After A 29% Drop - Yahoo Finance
Acadia Pharmaceuticals (ACAD) Stock May Be Mispriced After Mixed Phase III Push - simplywall.st
Acadia Pharmaceuticals (ACAD) Shares Drop After Phase 2 RADIANT Study Results - GuruFocus
Acadia Pharmaceuticals drops 7%, continuing fall after drug trial results (ACAD:NASDAQ) - Seeking Alpha
Acadia Pharmaceuticals' Risk-Reward Favorable After Remlifanserin Data, Deutsche Bank Says - Yahoo Finance
Ware Malcomb says construction finished on Acadia Pharmaceuticals’ Princeton office - ROI-NJ
Acadia Pharmaceuticals Fell 19% Today. Here’s Where the Stock Could Go in 2026 - Yahoo Finance
Biotech Rattled On Surprise Setback For Alzheimer's Drug - Investor's Business Daily
ACADIA Pharmaceuticals (ACAD) Drops 8.6% to $23.25 - AlphaStreet
Why Is Acadia Pharmaceuticals Stock Tumbling Today?ACADIA Pharmaceuticals (NASDAQ:ACAD) - benzinga.com
Acadia Pharmaceuticals: Remlifanserin Is In Trouble (NASDAQ:ACAD) - Seeking Alpha
Acadia Pharmaceuticals shares slide on mixed Alzheimer's psychosis data - Yahoo Finance
Acadia slides on Phase 2 miss in Alzheimer’s psychosis but keeps moving asset forward - biospace.com
Acadia Pharmaceuticals Shares Fall After RADIANT Phase 2 Study Misses Primary Endpoint - Yahoo Finance
ACADIA Pharmaceuticals' Shares Drop 10% Pre-Bell After Remlifanserin Study Misses Main Endpoint - Yahoo Finance
Acadia Pharmaceuticals Announces Phase 3 Enabling Topline Results from Phase 2 RADIANT Study of Remlifanserin for the Treatment of Alzheimer’s Disease Psychosis (ADP) - Yahoo Finance
ACADIA Pharmaceuticals Inc. (ACAD) Discusses Top-Line Phase II Results From RADIANT Study of Remlifanserin in Alzheimer's Disease PsychosisSlideshow (NASDAQ:ACAD) 2026-09-24 - Seeking Alpha
ACADIA Pharmaceuticals (ACAD) Gets ‘Sell’ Rating on Weak Trial Results, Shares Fall 13% - Yahoo Finance
2.45%
大文字化:
|
ボリューム (24 時間):